HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

AbstractOBJECTIVES:
To describe cases of new onset of inflammatory bowel disease (IBD) in patients with inflammatory rheumatic disease (IRD) receiving anti-TNF-α therapy.
METHODS:
A call for observations of such cases was sent to members of the French "Club rhumatismes et inflammation". Only patients without intestinal symptoms before introduction of anti TNF-α agents were included.
RESULTS:
During a 2-year period, 16 patients were declared: nine men and seven women, mean age 41.5 ± 17.4 years, 12 patients with ankylosing spondylitis, one with rheumatoid arthritis, one with psoriatic arthritis and two juvenile idiopathic arthritis with enthesitis related arthritis. Overall, 14 patients received etanercept and two had infliximab. The meantime frame between onsets of anti-TNF--α drugs and development of IBD was 29.3 ± 20.1 months. According to endoscopic and histological findings, IBD was classified as typical Crohn's disease in eight cases, Crohn's-like disease in six cases, indeterminate in one case and definite ulcerative colitis in one case. For all cases, each TNF-α blocking agent was discontinued and replaced by another monoclonal anti TNF-α antibody. After a mean follow up period of 23.4 ± 19.5 months, outcome was favorable without recurrent or flaring IBD.
CONCLUSIONS:
Paradoxical IBD may occur during anti TNF-α therapy for inflammatory rheumatic disease, mostly in patients with spondylarthropathies while receiving etanercept, at a frequency estimated to 0.15% in the French patients with spondylarthropathies exposed to TNF-α antagonists. The IBD mainly corresponded to Crohn's or Crohn's-like disease. On the contrary, new onset IBD is less frequently observed in other cases of IRD and with other TNF--α blockers.
AuthorsÉric Toussirot, Éric Houvenagel, Vincent Goëb, Damien Fouache, Antoine Martin, Philippe Le Dantec, Emmanuelle Dernis, Daniel Wendling, Thiphaine Ansemant, Jean-Marie Berthelot, Brigitte Bader-Meunier, Bernadette Kantelip, Le CRI
JournalJoint bone spine (Joint Bone Spine) Vol. 79 Issue 5 Pg. 457-63 (Oct 2012) ISSN: 1778-7254 [Electronic] France
PMID22088934 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Juvenile (drug therapy, epidemiology)
  • Arthritis, Psoriatic (drug therapy, epidemiology)
  • Arthritis, Rheumatoid (drug therapy, epidemiology)
  • Child
  • Colitis, Ulcerative (chemically induced, epidemiology)
  • Crohn Disease (chemically induced, epidemiology)
  • Etanercept
  • Female
  • Follow-Up Studies
  • France (epidemiology)
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Incidence
  • Inflammatory Bowel Diseases (chemically induced, epidemiology)
  • Infliximab
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Retrospective Studies
  • Rheumatic Diseases (drug therapy, epidemiology)
  • Spondylitis, Ankylosing (drug therapy, epidemiology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: